J
Judith Blankenburg
Researcher at Dresden University of Technology
Publications - 17
Citations - 184
Judith Blankenburg is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 9 publications receiving 62 citations.
Papers
More filters
Journal ArticleDOI
Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic
Judith Blankenburg,Magdalena K. Wekenborg,Jörg Reichert,Carolin Kirsten,Elisabeth Kahre,Luise Haag,L. Schumm,P. Czyborra,Reinhard Berner,Jakob Armann +9 more
TL;DR: In this paper , the authors conducted a 12 question Long-COVID19 survey and compared the responses on neurocognitive, general pain and mood symptoms from seropositive and seronegative adolescents.
Journal ArticleDOI
Lower household transmission rates of SARS-CoV-2 from children compared to adults.
Lukas Galow,Luise Haag,Elisabeth Kahre,Judith Blankenburg,Alexander H. Dalpke,Christian Lück,Reinhard Berner,Jakob Peter Armann +7 more
Posted ContentDOI
Mental Health of Adolescents in the Pandemic: Long-COVID-19 or Long-Pandemic Syndrome?
Judith Blankenburg,Magdalena K. Wekenborg,Jörg Reichert,Carolin Kirsten,Elisabeth Kahre,Luise Haag,Leonie Schumm,Paula Czyborra,Reinhard Berner,Jakob Peter Armann +9 more
TL;DR: In this article, the authors conducted a Long-COVID19 survey, comparing responses from seropositive and seronegative adolescents, and found that there was no statistical difference comparing the reported symptoms between seroppositive and non-seroppositives.
Journal ArticleDOI
Graves' disease after treatment with alemtuzumab for multiple sclerosis.
Elena Tsourdi,Matthias Gruber,Martina Rauner,Judith Blankenburg,Tjalf Ziemssen,Lorenz C. Hofbauer +5 more
TL;DR: Since autoimmune thyroid disease is common after alemtuzumab treatment for MS, pretreatment screening and careful follow-up may allow for early diagnosis and treatment.
Journal ArticleDOI
Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.
TL;DR: Analysis of event-driven immunoprofiling demonstrated that absolute numbers of Th1 and Th17 cells showed a reproducible increase starting 6 months before relapse activity, which appears to predict emergent disease activity when compared with stable disease.